MARTIN AND HARRIS LABORATORIES LIMITED was first established in 1996 and is based in Gurgaon, Haryana. The company is a part of Apeejay Group, which is India’s oldest and largest Conglomerates. Apeejay Group is a leading Industrial & Investment house with businesses in Automotive, Chemicals & Plastics, Distribution, Logistics & Retail, Pharmaceuticals & life sciences, real estate, and international trading and a nascent presence in IT, merchant banking & financial services and publishing.
Martin and Harris Laboratories Limited is primarily engaged in the business of manufacturing pharmaceuticals, medicinal chemicals & botanical products. The company intensively focuses on drugs used for Hyper Tension, High blood pressure, and heart attack. Apart from its primary business, the company also undertakes fund management through investment in different avenues like mutual funds, equity, etc.
Martin and Harris Laboratories Limited has two units located at Roorkee, Uttarakhand, and Una in Himachal Pradesh. The company is continuously striving to expand its manufacturing facilities and meet global standards.
The company was awarded ‘Best Pharma Excellence awards’ in 2018 by ASSOCHAM India.
CIN of Martin and Harris Laboratories |
U24239HR1993PLC033630 |
Registration Date of Martin and Harris Laboratories |
22 July 1993 |
Category/Sub-category of Martin and Harris Laboratories |
Company Limited by Shares |
Martin and Harris Laboratories Registered office address |
NH-8, Delhi Jaipur Highway, Village, Pachgaon (Fazalwas), District Gurgaon, Haryana |
Martin and Harris Laboratories Registrar and Transfer Agent address and contact details |
NA |
|
Name and Description of main products/services |
NIC Code of the product/service |
% to total turnover of the Company |
|
Manufacture of Pharmaceutical, Medicinal Chemical & Botanical Products |
210 |
52.03% |
|
Fund management activities |
663 |
47.97% |
MR. S. L. LAAD
MR. G. K. NIGAM
MR. AJAY GROVER
MR. H. S. THAKUR
|
Name of the Company |
% of shares held |
|
Delite Infrastructure Private limited |
100.00% |
|
S. No. |
Shareholders’ Name |
Number of shares |
% of total Shares of the company |
|
1 |
Promoters Shareholding |
140 |
0.004% |
|
2 |
Public Shareholding |
39,95,900 |
99.996% |
|
|
Total |
39,96,040 |
100.00% |
Indian Pharmaceutical market ranks as 3rd largest in the world in terms of volume and 14th largest in terms of value. Healthcare has become one of the largest sectors of the Indian economy, in terms of both employment and revenue. India is known as the Pharmacy of the world and is the largest provider of generic drugs at a global level. The pharmaceutical industry of India supplies over 50% of the global demand for various vaccines, 40% of generic demands in the USA, and 25% of all the medicines in the United Kingdom. Excellent Research & Development, low cost of labor, availability of management and technical personnel, and local equipment’s availability has helped India to manufacture pharma products at a very low cost.
The Indian healthcare market may see a 3 fold jump in terms of value to reach US$ 372 billion by FY 2022. The growth can be attributed to rising income, greater health awareness, increased precedence of lifestyle disease, and Indian prominence in making medicinal products for the treatment of COVID 19. India aims to achieve vaccination for COVID-19 of 30 Crore people in the next few months.
Export of Pharmaceuticals products from India stood at US$ 16.8 billion in FY 2020 and US$ 2.07 billion in the month of October 2020. In the first 3 quarters of FY 2021, India exported pharmaceuticals worth US$ 15.86 billion. India supplied around 45 tons and 400 million tablets of hydroxychloroquine to around 114 countries globally to treat the covid patients in the initial stage of the covid-19 pandemic. Exports in FY 2021 of Indian pharma products are expected to cross US$ 24 billion, increasing by over 16% when compared to FY 2020.
After the onset of COVID 19, the Indian pharmaceutical sector became the busiest sector in the Indian economy. The pandemic proved to be a boon in disguise for the Indian pharmaceutical sector.
